Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 13, 2021

Low-Dose Dasatinib in Older Patients With CML in Chronic Phase

The Lancet Haematology


Additional Info

The Lancet Haematology
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial
Lancet Haematol 2021 Dec 01;8(12)e902-e911, K Murai, H Ureshino, T Kumagai, H Tanaka, K Nishiwaki, S Wakita, K Inokuchi, T Fukushima, C Yoshida, N Uoshima, T Kiguchi, M Mita, J Aoki, S Kimura, K Karimata, K Usuki, J Shimono, Y Chinen, J Kuroda, Y Matsuda, K Nakao, T Ono, K Fujimaki, H Shibayama, C Mizumoto, T Takeoka, K Io, T Kondo, M Miura, Y Minami, T Ikezoe, J Imagawa, A Takamori, A Kawaguchi, J Sakamoto, S Kimura

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading